Development of a rapid genotype assay for warfarin dosing assessment using Taqman probe and Real-Time PCR (real-time polymerase chain reaction technology). PG 1639、1075, and 0430
With PG1639, only one PCR reaction was required per assay to detect VKORC1 (-1639) genotype as GG, GA or AA.
The test is performed by comparing the sample position with the positions of the three isoforms. PG0430 detects CYP2C9*2 (c.430) sites as CC, CT or TT, and PG1075 detects CYP2C9*3 (c.1075) sites as AA, AC or CC.
PG1639, PG1075, and PG0430 were identified for Warfarin dosing assessment genotypes.
VKORC1 and CYP2C9 partial locus variants have been found to be highly relevant to the maintenance dose of Warfarin .
Warfarin, which does too low to be effective, produces blood clots and ，conversely it causes unanticipated massive bleeding.
Individual genes allow anticoagulants to adjust to the most appropriate dose, so the FDA recommends genetic testing before use to enhance drug safety.
Clopidogrel ( Plavix)， relating to disease: atherosclerotic events in patients with stroke, myocardial infarction or peripheral arterial vascular disease (e.g., myocardial infarction, stroke, or other death due to vascular disease)
